Structural and Functional Assessment of Macula in Patients with High-Risk Proliferative Diabetic Retinopathy Submitted to Panretinal Photocoagulation and Associated Intravitreal Bevacizumab Injections: A Comparative, Randomised, Controlled Trial

Autor(es)

Preti, Rony Carlos ^[1] ; Vasquez Ramirez, Lisa Marie ^[1] ; Ribeiro Monteiro, Mario Luiz ^[1] ; Pelayes, David E. ^{[2, 3]} ; Takahashi, Walter Yukihiko ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med, Div Ophthalmol, Sao Paulo - Brazil

^[2] Univ Buenos Aires, Area Ophthalmol, Buenos Aires, DF - Argentina

^[3] Maimonides Univ, Ctr Appl Res & High Complex Ophthalmol, Buenos Aires, DF - Argentina

• Tipo de documento: Artigo Científico
• Fonte: OPHTHALMOLOGICA; v. 230, n. 1, p. 1-8, 2013.
• Citações Web of Science: 10

Resumo

Purpose: To compare the efficacy of therapy with panretinal photocoagulation (PRP) and intravitreal bevacizumab (IVB) injections versus PRP alone in patients with high-risk proliferative diabetic retinopathy (HR-PDR) with a 6-month follow-up. Methods: Forty-two patients with HR-PDR were prospectively studied in a randomised, masked, controlled trial. Both eyes of each patient were randomised either to the study group (SG) receiving PRP plus IVB injections or the control group (CG) receiving PRP alone. Mean change in visual acuity (VA), optical coherence tomography-measured fovea! thickness (FT) and macular volume (MV) were compared. Results: Intergroup comparisons showed no significant difference in VA while FT exhibited a significant (p < 0.05) difference at 1 month of follow-up and MV was significantly reduced at the 1- and 3-month follow-up. Compared to baseline, VA was significantly worse at all follow-ups in the CG and was stable in the SG. FT increased significantly in the CG from baseline to the 1- and 6-month follow-ups and in the SG, no significant difference was observed. MV was significantly increased in the CG during all follow-up periods. Conclusion: In HR-PDR, using IVB injections as adjuvant treatment to PRP reduces the VA deterioration and results in decreased FT and MV measurements compared to PRP alone. Copyright (C) 20135. Karger AG, Basel (AU)

• Processo FAPESP: 09/08895-1 - Avaliação estrutural e funcional da mácula nos pacientes com retinopatia diabética proliferativa submetidos à panfotocoagulação associada a bevacizumab
• Beneficiário: Walter Yukihiko Takahashi
• Linha de fomento: Auxílio à Pesquisa - Regular